NCT03806101View on ClinicalTrials.gov

Study of PF-04965842 Effect on Rosuvastatin Pharmacokinetics in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 23, 2019

Primary Completion Date

March 15, 2019

Study Completion Date

April 11, 2019

Conditions
Healthy
Interventions
DRUG

PF-04965842

200 mg dose of PF-04965842 once daily (QD) for 3 days

DRUG

Rosuvastatin

Single 10 mg dose of rosuvastatin

Trial Locations (1)

B-1070

Pfizer Clinical Research Unit, Brussels

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT03806101 - Study of PF-04965842 Effect on Rosuvastatin Pharmacokinetics in Healthy Participants | Biotech Hunter | Biotech Hunter